MAPT and Alzheimer disease: Recent studies suggested that phosphorylated tau protein 217 could serve as a reliable biomarker for AD (Mattsson-Carlgren et al., 2024), detectable with ultra-sensitive graphene field-effect transistor sensors (Wang et al., 2024).